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SERONEGATIVE 

SPONDYLOARTHROPATHIES · A REVIEW 

PART 11: GENETICS AND PATHOGENESIS 

A.A. BORG, P.T. DAWES, T .E. HOTHERSALL 
INTRODUCTION 
In none of the spondyloarthropathies is the 
pathogenesis well understood. Much of the 
investigation into the aetio-pathogenesis of 
these diseases has focused on the associa­
tion with HLA-B27 and the known trigger­
ing potential of certain infectious agents. 
THE HLA LINKED GENES 
The HLA linked genes are subdivided into 
three groups: class I, class II and class rn, 
which are structurally and functionally dis­
tinct. The class I genes, HLA-A, Band C 
code for the classical transplantation anti­
gens expressed on the surface of all nucle­
ated cells. 
The class I antigens are recognised in con­
junction with antigen by the T -cell receptor 
of cytotoxicT-lymphocytes and they there­
fore form the target for self-recognition. The action of 
cytotoxic T -cells against autologous cells which are 
either infected or chemically modulated or which show 
malignant transformation, is considered to be one of the 
most important functions of immunological surveillance 
(1). The class I antigens are associated with the 
spondyloarthropathies. 
The class II molecules are recognised in conjunction 
with antigens on the surface of macrophages/monocytes 
by the T -cell receptors. Upon cross-linking, these initiate 
a cascade of biochemical reactions resulting in activa­
tion of the T -cell (2). 
Both class I and class II MHC-encoded molecules have 
distinct but related , functional requirements in immune 
recognition . The class I molecules primarily bind 
anti genic peptides available to them in their biosynthetic 
journey from the rough endoplasmic reticulum to the 
plasma membrane, while class 11 molecules bind 
proteolytic fragments deri ved from endocytosed 
extracellular proteins generated in acidic cellular com­
partments (Figure I) (3). This functional distinction can 
be illustrated further by the mutually exclusive expres­
FIGURE I 
Model for selj~peptides hound in groove ofMHC class 1 molecules. 
The hackbone structures of the class I molecule are indicated by 
rihholls. The black circles depict the side-chains of those residues 
that are critical in the interaction with the bound peptide ofHLA-B27. 
mature T -cells that are committed to the class I - and class 
11 - peptide complexes respectively (4). 
Certain class I or class II genotypes might provide a 
defect in the T -cell repertoire , which could lead to the 
type of autoimmunity seen in HLA-associated diseases 
(5). The class II site is associated with subsets of RA. 
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sion of the CD8 and CD4 'coreceptor' molecules on 
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The class III region of the HLA chromosome contains 
the genes for thc complement components C4, Bfand C2 
as well as the gcnes for the C21-hydroxylase. C2 and C4 
are important factors in the classical pathway, while Bf 
is the proactivator of C3 in the alternate pathway of 
complement activation. Their immunological impor­
tance is best documentcd by the observation of severe 
lupuslike syndromes in the rare cases of genetic defi­
ciency of C2 or C4 (6). 
HLA·B27 AND CLINICAL SUBSETS 
Since its discovery in 1973 as a genetic marker, HLA­
B27 typing continues to be very useful in broadening our 
views of the clinical spectrum of these diseases (7). One 
such example is the atypical clinical presentation of 
patients with back inflammation who have normal sacro­
iliac and spinal radiographs (8). 
In children, peripheral arthritis and enthesitis are the 
usual presenting features of a spondyloarthropathy and 
low back pain symptoms or sacroilitis are infrequent. 
The finding of HLA-B27 and/or a family history of 
spondylitis can be useful in diagnosing a spondy­
loarthropathy (9). 
The structure and function of HLA-B27, its molecular 
sub-types (B*2701-B*2706) and other class I major 
histocompatibility complex (MHC) antigens has been 
recently established by molecular genetic studies and 
crystallisation (10). Most of the sUbtypes appear to 
predispose to disease development. Up to 20% of HLA­
B27 positive individuals develop Ankylosing Spondylitis 
(AS) or develop Reiter's Syndrome (RS) (11). An off­
spring of an individual with HLA-B27 has a 50% chance 
of carrying the same antigen, thus conferring an overall 
10% chance of developing AS or RS if exposed to a 
specific environmental trigger. 
The risk for B27-positive relatives of B27-positive pa­
tients ranges from 25-50% (12-14). HLA-B27 negative 
TABLE I 
Frequency ofHLA -827 in different healthy populations. 
POPULATION 	 % 
Japan <I 

Black (Africa) <I 

Black (USA) 3-4 

Pima Indians (USA) 18 

Haida Indians (Canada) 50 

Caucasians: 
London (UK) 6 

Geneva (Switzerland) 7 

Los Angeles (USA) 8 

Edmonton (Canada) 9 

Zagreb (Yugoslavia) 14 

Helsinki (Finland) 14 

relatives of patients with AS also have an increased 
incidence of developing a spondyloarthropathy, thus 
genetic factors other than HLA-B27 must be involved in 
the pathogenesis. 
It has long been recognised that AS occurs more rarely 
in non-Caucasian populations. This may be related to the 
different prevalence ofHLA-B27 in different populations 
(Table I). HLA-B27 occurs in less than I % of Japanese 
and black Africans. The disease is very rare in the former 
group and almost unknown in the latter. In the American 
Indian, B27 prevalence ranges from 18% to 50%, and AS 
is consequently more frequent (15). 
There is a striking family history of different disease 
expressions in the Seronegative Spondyloarthropathies. 
In a study of first degree relatives of patients with 
Psoriatic Arthritis, Wright et al (16), showed a family 
history of Psoriasis in21 %. Psoriatic Arthritis occured in 
4.4%, Ulcerative Colitis in 0.9%, AS in 5.6% and sacro­
iliitis in 7%. 
CURRENT HYPOTHESES 
Hypotheses linking the Spondyloarthropathies with HLA­
B27 include (17-19) : 
1. 	 B27 acting as a receptor site for an infective agent. 
2. 	 B27 being a marker for a gene close by on chromo­
some 6 that determines susceptibility to an unknown 
trigger. 
3. 	 B27 inducing tolerance to cross-reactive foreign 
antigens - Molecular Mimicry (20) ego Klebsiella 
(21), Shigella, Chlamydia, and Yersinia (22). 
The hypothesis which has received most attention is 
molecular mimicry between HLA B27 antigen and mi­
crobial antigens. Special attention has been focused on 
Klebsiella pneumoniae, which is frequently isolated in 
faeces of AS patients with an active disease or with acute 
anterior uveitis and is also increased in asymptomatic AS 
patients (23-24). AS patients with an active disease have 
an increased level ofIgA anti-Klebsiella antibodies (25) , 
and the presence of faecal Klebsiella is associated with 
elevation of serum C-reactive protein (26-27). 
Geczy and co-workers have carried out a number of 
studies on the association between HLA-B27, AS and 
Klebsiella (28) . Their studies showed that HLA B27 
positive AS patients had significantly impaired in vitro 
Iymphoproliferative responses to Klebsiella antigens 
when compared to HLA B27 positive or negative normal 
controls. They also observed that antibodies raised in 
rabbits against a certain Klebsiella isolate specifically 
lysed HLA B27 positive Iymphocytes of AS patients 
(29). 
In other experiments, Geczy and co-workers (30-31) 
showed that a modifying factor in the culture filtrate of 
a certain Klebsiella isolate was able to make HLA B27 
positive lymphocytes from healthy subjects susceptible 
to lysis by anti-Klebsiella serum. The same result could 
---
--
I 
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be reached by using virus-transformed cell lines ob­
tained from HLA B27 positive AS patients. 
This characteristic of certain Klebsiella bacteria is asso­
ciated with the presence of a plasmid in the bacterium. 
The plasmid could be transferred to other enterobacteria, 
which then acquired the ability to elaborate the modify­
ing factor (32). Some isolates of Salmonella, Shigella, 
Escherichia and Campylobacter strains can also elabo­
rate this modifying factor (33). 
McGuigan et al (34), have shown that cross-reactivity is 
shared by all enteric organisms isolated from HLA B27 
positive AS patients, and that organisms with this prop­
erty persist for more than one year in the bowel flora of 
these patients. 
The observations ofGeczy and his co-workers are in line 
with studies suggesting that HLA molecules may serve 
as reeeptors for microorganisms (35). Binding of bacte­
ria by HLA antigens is nonspecific. since HLA A, Band 
C molecules bind equally well and do not distinguish one 
strain from another (36). A blind confirmation of the so­
called Geczy factor in British (37) and Dutch (38) AS 
patients has been carried out, but the real nature and 
significance of the factor remains perplexing. 
TABLE 11 
DISEASE 
SPONDYLOARTHROPATHIES 
Ankylosing spondylitis 

Reiter's disease 

Psoriatic arthritis 

Reactive arthritis -

Yersinia 

Salmonella 

1- OTHER RHEUMATIC CONDITIONS 
Behcet's disease 

Rheumatoid arthritis 

Systemic lupus erythematosus 

Scleroderma 

Sjogren's syndrome (Primary) 

Giant Cell arteritis 
Some HLA associations ill the Spondyloarthropathies and o!lwr rheumatic conditions. 
HLAANTIGEN FREQUENCY FREQUENCYl 
INPATIENTS IN CONTROLS 
(%) (C;, ) ~ 
B27 80-100 6-8 
B27 60-85 6-8 
B27 20-50 6-8 
B38 20-45 2-8 
B39 20-30 2-6 
DR7 30-45 15-20 
OR4 40-50 20-30 
B27 50-75 6-::\ 

B27 50-70 6-8 

B5 20-85 10-25 

DR4 45-75 20-30 

DR2 45-55 20-30 

DR3 40-50 15-25 

OR5 35-45 20-25 

B8 35-60 15-25 

OR3 50-65 15-25 

OR3 30 15-25 

DR4 40-50 20-30 

The human HLA-B27 and Beta 2 microglobulin genes 
have been successfully transfected and expressed into 
normal rats. Several strains of these animals then de­
velop arthritis, enthesitis, psoriasiform skin lesions, 
onychodystrophy, urethritis or orchitis. 
Diarrhoea is the first manifestation and inflammatory 
lesions are found in the gut resembling human inflamma­
tory bowel disease (39). The significance of this obser­
vation is not clear in view of the similar findings in rats 
with adjuvant arthritis. 
AS is the protoytpe of the Spondyloarthropathies (40). 
There is no conclusive evidence implicating a specific 
infectious agent as the precipitating pathogen. Extensive 
microbiological studies of peripheral joints have failed 
to detect intra-articular sepsis (21). However, a great 
deal of evidence both clinical and immunological has 
been accumulated to support the role of infectious agents 
through an indirect action in the pathogenesis ofAS (41), 
possibly via the mucosal immune system. 
In AS and other seronegative spondyloarthropathies 
there are increased scrum levels of IgA (particularly of 
the secretory type) and circulating immune complexes 
(42-43). Inflammatory gut lesions have been found in 
after Moll, 1987. 
-I 
- - - - -
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65% of patients with reactive arthritis and in 57% of AS 
patients. A good correlation was also shown between the 
presence of gut inflammation in biopsy specimens and 
the persistence of peripheral joint inflammation (44). 
These findings suggest that environmental factors lead 
to an increase in the permeability ofthe intestinal wall or 
disturb local immunological defence mechanism allow­
ing the entry ofbacterial antigens into the circulation and 
induction of joint inflammation (45). 
Several of the infectious agents that trigger Reiter's 
syndrome or Reactive arthritis are known, in sharp 
contrast to AS or psoriatic arthropathy. Antigens (but not 
viable organisms) of Chlamydia (46-47), Yersinia (48) 
and Salmonella (49) have been detected in the affected 
joints by using monoclonal antibodies and Western 
blotting. 
This finding suggests a failure of the normal immune 
response to eradicate the antigens or the persistence of 
viable organisms shedding antigens chronically into the 
joints. 
Although the factors leading to the location and persist­
ence ofthe bacteria are not clearly known, these findings 
may provide a rationale for long-term antibiotic treat­
ment. 
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